Taha Johanna Henning, Orestis Rakitzis, Jakob Kaminski, Linda Kokwaro, Daniel Fürstenau, Sonia Lech, Stefanie Schreiter
{"title":"[Scoping review on the identification and evaluation of available digital applications for bipolar disorder].","authors":"Taha Johanna Henning, Orestis Rakitzis, Jakob Kaminski, Linda Kokwaro, Daniel Fürstenau, Sonia Lech, Stefanie Schreiter","doi":"10.1007/s00115-025-01857-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorders require long-term monitoring. Digital applications, such as smartphone apps, offer potential for self-management and early detection but there are uncertainties regarding availability, guideline conformity and evidence. In Germany, specific digital health applications (DiGAs) for bipolar disorders are lacking, highlighting regulatory and healthcare delivery challenges.</p><p><strong>Aim: </strong>This review examines apps for bipolar disorder available in Germany with respect to their functions, availability and evidence base.</p><p><strong>Material and methods: </strong>Between January and March 2025 a systematic search was conducted in the databases MindApps.org and MindTools.io for apps. Functions, research evidence, languages, cost models, and app-store availability were recorded. Additionally, scientific studies on the identified apps were reviewed.</p><p><strong>Results: </strong>A total of 18 apps were identified 11 of which are specifically for bipolar disorders. The functions range from mood and symptom tracking to psychoeducational contents. Of the apps six had published studies but none showed significant improvements in symptoms.</p><p><strong>Discussion: </strong>Although digital interventions show promise for improving the treatment of bipolar disorder, large-scale, methodologically rigorous randomized controlled trials with standardized endpoints are still lacking. In Germany no DiGAs specifically designed for this patient group are currently available. Moreover, for sustainable integration into routine care of a chronic condition such as bipolar disorder, dependable reimbursement models and comprehensive long-term studies are also required.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"423-431"},"PeriodicalIF":1.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411593/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nervenarzt","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00115-025-01857-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bipolar disorders require long-term monitoring. Digital applications, such as smartphone apps, offer potential for self-management and early detection but there are uncertainties regarding availability, guideline conformity and evidence. In Germany, specific digital health applications (DiGAs) for bipolar disorders are lacking, highlighting regulatory and healthcare delivery challenges.
Aim: This review examines apps for bipolar disorder available in Germany with respect to their functions, availability and evidence base.
Material and methods: Between January and March 2025 a systematic search was conducted in the databases MindApps.org and MindTools.io for apps. Functions, research evidence, languages, cost models, and app-store availability were recorded. Additionally, scientific studies on the identified apps were reviewed.
Results: A total of 18 apps were identified 11 of which are specifically for bipolar disorders. The functions range from mood and symptom tracking to psychoeducational contents. Of the apps six had published studies but none showed significant improvements in symptoms.
Discussion: Although digital interventions show promise for improving the treatment of bipolar disorder, large-scale, methodologically rigorous randomized controlled trials with standardized endpoints are still lacking. In Germany no DiGAs specifically designed for this patient group are currently available. Moreover, for sustainable integration into routine care of a chronic condition such as bipolar disorder, dependable reimbursement models and comprehensive long-term studies are also required.
期刊介绍:
Der Nervenarzt is an internationally recognized journal addressing neurologists and psychiatrists working in clinical or practical environments. Essential findings and current information from neurology, psychiatry as well as neuropathology, neurosurgery up to psychotherapy are presented.
Review articles provide an overview on selected topics and offer the reader a summary of current findings from all fields of neurology and psychiatry.
Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange.
Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.